Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allena Pharmaceuticals Inc.

www.allenapharma.com

Latest From Allena Pharmaceuticals Inc.

Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive

Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.

 

Deals Rare Diseases

Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Gynecological, Urological
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allena Pharmaceuticals Inc.
  • Senior Management
  • Louis Brenner, MD, CEO
    Edward Wholihan, CFO
    Annamaria Kausz, MD, VP, Clinical Dev.
  • Contact Info
  • Allena Pharmaceuticals Inc.
    Phone: (617) 467-4577
    One Newton Executive Pk.
    Ste. 202
    Newton, MA 02462
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register